WHO reviews confirm GLP‑1 drugs trigger major weight loss, but safety questions linger

The WHO's Tripartite Review of GLP‑1 Therapies

In a coordinated effort, three independent panels commissioned by the World Health Organization examined the emerging data on glucagon‑like peptide‑1 (GLP‑1) receptor agonists. The panels, each drawing on a different pool of clinical trials, converged on a striking finding: the drugs—tirzepatide, semaglutide and liraglutide—can produce weight reductions that rival, and in some cases exceed, those achieved by bariatric surgery.

Efficacy Across the GLP‑1 Class

Across the studies, participants with a body‑mass index above 30 lost, on average, between 12 and 22 percent of their initial weight after a year of treatment. Tirzepatide, marketed as Mounjaro and Zepbound, led the pack with the highest mean loss, while semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) also posted substantial declines.

Funding Shadows and Safety Gaps

Researchers cautioned that the bulk of the trial data originated from studies sponsored by the manufacturers of the drugs. "When the sponsor also funds the analysis, there is an inherent risk of bias," said Dr. Elena Martínez, an epidemiologist at the University of Barcelona. The WHO panels noted that long‑term safety remains under‑documented, particularly concerning cardiovascular outcomes beyond the trial windows.

Side‑Effect Profile and Real‑World Implications

Nausea, vomiting and transient gastrointestinal discomfort were the most frequently reported adverse events. In some trials, up to 30 percent of participants discontinued therapy because of intolerable nausea. "Patients need to weigh rapid weight loss against the daily reality of feeling sick," observed endocrinologist Dr. Samuel Okeke of Lagos University Teaching Hospital.

Looking Ahead

The WHO concluded that GLP‑1 agonists represent a powerful tool in the fight against obesity, but they urged policymakers to pair drug access with robust post‑marketing surveillance. The panels called for independent, long‑term studies that could clarify cardiovascular risk, cancer incidence, and metabolic consequences over a decade or more.